Endocrinology, Diabetes & Metabolism · Nov 1, 2026

Comparative Efficacy and Safety of Saroglitazar and Dapagliflozin on Hepatic Steatosis and Glycemic Control in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A 25‐Week Prospective Multicenter Comparative Cohort Study

By Gupta M, Chandra KP, Awasthi R et al.

Introduction: Metabolic dysfunction‐associated steatotic liver disease ( MASLD ) is the leading cause of chronic liver disease globally, driven by rising obesity and type 2 diabetes mellitus ( T2DM ). Existing medications provide minimal fibrosis regression, highlighting the need for comparative evidence on agents with metabolic and hepatic benefits. This study compared the efficacy and safety of saroglitazar 4 mg and dapagliflozin 10 mg in patients with MASLD . Methods: This 25‐week, prospective, multicentre, open‐label active‐controlled comparative cohort study enrolled adults aged 18–70 years with MASLD confirmed by FibroScan (steatosis grade S3 , controlled attenuation parameter [ CAP ] ≥ 292 dB /m, and/or fibrosis stage ≥ F2 , liver stiffness measurement [ LSM ] ≥ 8.0 kPa ). Participants received saroglitazar ( n = 27) or dapagliflozin ( n = 27) once daily, added to standard of care per physician discretion. The primary endpoint was change from baseline in hepatic steatosis ( CAP ) and fibrosis ( LSM ); secondary endpoints included HbA1c , hepatic enzymes, lipid profile, and adverse events. Results: All 54 participants completed follow‐up. CAP decreased from 314.7 to 278.7 dB /m with saroglitazar and from 310.2 to 287.0 dB /m with dapagliflozin (between‐group p = 0.44). LSM decreased in both arms (saroglitazar −0.96 kPa ; dapagliflozin −0.46 kPa ; between‐group p = 0.80). HbA1c improved in both groups (saroglitazar 8.28%–6.76%; dapagliflozin 8.14%–7.30%), with a significantly greater reduction with saroglitazar (between‐group p = 0.04). ALT and AST declined similarly in both arms despite higher baseline ALT with saroglitazar. Triglycerides decreased significantly within both groups (saroglitazar −62.5 mg/ dL ; dapagliflozin −28.3 mg/ dL ), with no significant between‐group difference. No treatment‐emergent adverse events, including edema, occurred in either group. Conclusions: Both saroglitazar and dapagliflozin improved hepatic steatosis, fibrosis markers, liver enzymes, and glycemic control over 25 weeks, with comparable hepatic benefit. Saroglitazar produced a significantly greater reduction in HbA1c , suggesting a possible glycemic‐preferential advantage in patients requiring simultaneous glycemic and hepatic control; larger randomized trials are needed to confirm any differential hepatic efficacy. Trial Registration: Clinical Trials Registry of India, CTRI /2024/08/071848

doi.org/10.1002/edm2.70377Open accessPubMed 42967591Interventions

AgingResearch.News